To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.

To develop cell culture and small animal models of Nipah virus replication and pathogenesis in a biosafety level (BSL) 4 lab.

To investigate long-acting PrEP formulations in macaque subjects.

To engage partners and stakeholders on awareness and education for infection associated chronic conditions (IACC).

To engage communities through the power of arts and culture to educate, empower and mobilize individuals toward positive change. Thriving Together Atlanta serves as a model of how cross-sector partnerships can address multifaceted issues affecting communities today.

To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To evaluate the safety, pharmacokinetics and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir (EFdA) when administered vaginally to pigtailed macaques.

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To support implementation of a set of recommendations and a roadmap developed in the "Strengthening Public Health and Community Based Organization (CBO)" Interface report.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To support efforts to strengthen and expand existing infection prevention control activities in various countries across Sub-Saharan Africa.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) in HIV-uninfected populations.